Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23182188 | 0.78 | PDK1 (0.45) | PDK1SCN9ASLC8A1 | |
| SCHEMBL28506422 | 0.78 | PDK1 (0.45) | PDK1SCN9ASLC8A1 | |
| SCHEMBL18125939 | 0.78 | PDK1 (0.45) | PDK1SCN9ASLC8A1 | |
| SCHEMBL3937696 | 0.77 | PDK1 (0.44) | PDK1SCN9ASLC8A1 | |
| SCHEMBL23700663 | 0.71 | USP2 (0.49) | PDK1MAPTSCN9ARECQLMEN1 | |
| SCHEMBL23700662 | 0.71 | USP2 (0.49) | PDK1MAPTSCN9ARECQLMEN1 | |
| SCHEMBL28132263 | 0.69 | PDK1 (0.62) | PDK1SCN9AMEN1TP53KMT2A | |
| SCHEMBL28133029 | 0.69 | PDK1 (0.62) | PDK1SCN9AMEN1TP53KMT2A | |
| SCHEMBL27785370 | 0.69 | PDK1 (0.62) | PDK1SCN9AMEN1TP53KMT2A | |
| SCHEMBL13632338 | 0.69 | KMT2A (0.65) | MAPTPOLBRECQLMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PDK1 1689/4885MAPT 3645/4885POLB 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.